FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Baity Glenn 		2. Issuer Name and Ticker or Trading Symbol

ACADIA PHARMACEUTICALS INC [ ACAD ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
EVP AND GC
(Last)          (First)          (Middle)

3611 VALLEY CENTRE DRIVE, SUITE 300 		3. Date of Earliest Transaction (MM/DD/YYYY)

10/4/2017
(Street)

SAN DIEGO, CA 92130
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   10/4/2017     M    6500   A $1.62   74156   D  
 
Common Stock   10/4/2017     M    4500   A $2.18   78656   D  
 
Common Stock   10/5/2017     M    1000   A $2.18   79656   D  
 
Common Stock   10/5/2017     M    7500   A $1.62   99656   D  
 
Common Stock   10/5/2017     M    20000   A $2   107156   D  
 
Common Stock   10/5/2017     S (1)    37500   (2) D $40.9078   69656   D  
 

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   $1.62   10/4/2017     M         6500      (3) 3/24/2021   Common Stock   6500   $0   7500   D  
 
Stock Option (right to buy)   $2.18   10/4/2017     M         4500      (4) 3/22/2022   Common Stock   4500   $0   125500   D  
 
Stock Option (right to buy)   $2.18   10/5/2017     M         1000      (4) 3/22/2022   Common Stock   1000   $0   124500   D  
 
Stock Option (right to buy)   $1.62   10/5/2017     M         7500      (3) 3/24/2021   Common Stock   7500   $0   0   D  
 
Stock Option (right to buy)   $2   10/5/2017     M         20000      (5) 10/19/2018   Common Stock   20000   $0   0   D  
 

Explanation of Responses:
(1)  The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2017.
(2)  The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.605 to $41.065 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
(3)  25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments.
(4)  25% of the shares subject to the Stock Option vested and became exercisable on March 23, 2013. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments.
(5)  50% of the shares subject to the Stock Option vested and became exercisable on October 20, 2010. The remaining shares vested and became exercisable thereafter in 24 equal monthly installments.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Baity Glenn
3611 VALLEY CENTRE DRIVE, SUITE 300
SAN DIEGO, CA 92130

EVP AND GC

Signatures
/s/ Glenn F. Baity 10/6/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Acadia Pharmaceuticals Charts.
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Acadia Pharmaceuticals Charts.